tegafur has been researched along with Cancer of the Thymus in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thymic carcinoma is a rare epithelial tumor of the thymus with a poor prognosis, and multimodal approaches are important for its treatment." | 2.94 | S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Study protocol of LOGIK1605/JART-1501. ( Ashizawa, K; Fukuda, M; Fukuoka, J; Funaki, S; Hara, M; Mukae, H; Nabeshima, K; Okumura, M; Sato, S; Seto, T; Sugio, K; Takenoyama, M; Tateyama, H; Yamazaki, T, 2020) |
| "There was no recurrence for more than 2 years after the lung surgery." | 1.46 | [A Recurrent Case of Thymic Adenocarcinoma Effectively Treated with S-1 Over a Long-Term Period]. ( Ikeda, H; Kakegawa, S; Matsumoto, I; Saito, D; Takata, M; Takemura, H; Tamura, M; Tanaka, Y; Yoshida, S, 2017) |
| "Thymic carcinoma is a rare intrathoracic malignant tumor, and the prognosis for patients with advanced stage of the disease is poor." | 1.36 | S-1 is an active anticancer agent for advanced thymic carcinoma. ( Hosomi, Y; Iguchi, M; Okamura, T; Okuma, Y; Shibuya, M; Shimokawa, T; Takagi, Y, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Tsukita, Y | 1 |
| Inoue, A | 1 |
| Sugawara, S | 1 |
| Kuyama, S | 1 |
| Nakagawa, T | 1 |
| Harada, D | 1 |
| Tanaka, H | 1 |
| Watanabe, K | 1 |
| Mori, Y | 1 |
| Harada, T | 1 |
| Hino, T | 1 |
| Fujii, M | 1 |
| Ichinose, M | 1 |
| Fukuda, M | 1 |
| Funaki, S | 1 |
| Yamazaki, T | 1 |
| Sato, S | 1 |
| Mukae, H | 1 |
| Takenoyama, M | 2 |
| Fukuoka, J | 1 |
| Nabeshima, K | 1 |
| Tateyama, H | 1 |
| Ashizawa, K | 1 |
| Hara, M | 1 |
| Seto, T | 2 |
| Okumura, M | 1 |
| Sugio, K | 1 |
| Okuma, Y | 3 |
| Goto, Y | 1 |
| Ohyanagi, F | 1 |
| Sunami, K | 1 |
| Nakahara, Y | 1 |
| Kitazono, S | 1 |
| Kudo, K | 1 |
| Tambo, Y | 1 |
| Kanda, S | 1 |
| Yanagitani, N | 1 |
| Horiike, A | 1 |
| Horinouchi, H | 1 |
| Fujiwara, Y | 1 |
| Nokihara, H | 1 |
| Yamamoto, N | 2 |
| Nishio, M | 1 |
| Ohe, Y | 1 |
| Hosomi, Y | 3 |
| Hirai, F | 1 |
| Inamasu, E | 1 |
| Toyokawa, G | 1 |
| Yoshida, T | 1 |
| Nosaki, K | 1 |
| Takenaka, T | 1 |
| Yamaguchi, M | 1 |
| Ichinose, Y | 1 |
| Kaira, K | 1 |
| Naruse, I | 1 |
| Imai, H | 1 |
| Sunaga, N | 1 |
| Hisada, T | 1 |
| Motegi, M | 1 |
| Asao, T | 1 |
| Yamada, M | 1 |
| Miyamoto, S | 1 |
| Shibuya, M | 2 |
| Okamura, T | 2 |
| Hishima, T | 1 |
| Takata, M | 1 |
| Matsumoto, I | 1 |
| Tanaka, Y | 1 |
| Saito, D | 1 |
| Yoshida, S | 1 |
| Kakegawa, S | 1 |
| Tamura, M | 1 |
| Takemura, H | 1 |
| Ikeda, H | 1 |
| Ono, A | 1 |
| Naito, T | 1 |
| Tagawa, T | 1 |
| Ohta, M | 1 |
| Kuwata, T | 1 |
| Awaya, H | 1 |
| Ishida, T | 1 |
| Shimokawa, T | 1 |
| Takagi, Y | 1 |
| Iguchi, M | 1 |
| Koizumi, T | 1 |
| Agatsuma, T | 1 |
| Komatsu, Y | 1 |
| Kubo, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| First-line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas[NCT05832827] | Phase 2 | 35 participants (Anticipated) | Interventional | 2023-09-04 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for tegafur and Cancer of the Thymus
| Article | Year |
|---|---|
Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoco | 2020 |
S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Study protocol of LOGIK1605/JART-1501.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Clinical | 2020 |
Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Kapl | 2020 |
8 other studies available for tegafur and Cancer of the Thymus
| Article | Year |
|---|---|
Results of S-1-based chemotherapy for platinum (and antrathycline)-refractory advanced thymic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Male | 2014 |
Dramatic Response of S-1 Administration to Chemorefractory Advanced Thymic Cancer.
Topics: Antimetabolites, Antineoplastic; Disease Progression; Drug Combinations; Female; Humans; Middle Aged | 2014 |
Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers; Disease Pro | 2016 |
[A Recurrent Case of Thymic Adenocarcinoma Effectively Treated with S-1 Over a Long-Term Period].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; Middle Aged; Ova | 2017 |
S-1 treatment for chemorefractory thymic carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Drug Combinations; Drug Resistance, Neoplasm; Humans; Immunoe | 2008 |
S-1 plus cisplatin chemotherapy with concurrent radiation for thymic basaloid carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Basal Cell; Cisplatin; Combined Modality | 2010 |
S-1 is an active anticancer agent for advanced thymic carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma; Disease Progression; Disease-Free Survival; Drug C | 2010 |
Successful S-1 monotherapy for chemorefractory thymic carcinoma.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Combinations; Drug Resistance, Neopl | 2011 |